SCHEMBL5755034

SCHEMBL5755034

CSc1nc2ccc(S(=O)(=O)N[C@@H](C(=O)NO)C(C)C)cc2s1

nearest known ligand 0.55

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
GAA P10253 1/20 0.55
HTT P42858 2/20 0.54
PKM P14618 1/20 0.54
GPR55 Q9Y2T6 1/20 0.54
HPGD P15428 2/20 0.53
TSHR P16473 2/20 0.53
LMNA P02545 1/20 0.53
HSP90AA1 P07900 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
TP53 P04637 1/20 0.52
ALOX15 P16050 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5757339 0.89 PKM (0.56) ALDH1A1GAAHTTPKMGPR55
SCHEMBL5755974 0.89 ALDH1A1 (0.55) ALDH1A1GAAHTTGPR55HPGD
SCHEMBL5756601 0.88 PKM (0.55) ALDH1A1GAAHTTPKMGPR55
SCHEMBL5754967 0.87 ALDH1A1 (0.53) ALDH1A1GAAHTTGPR55HPGD
SCHEMBL5755559 0.87 TP53 (0.52) ALDH1A1GAAHTTGPR55HPGD
SCHEMBL5755760 0.85 ALDH1A1 (0.51) ALDH1A1GAAHTTGPR55HPGD
SCHEMBL5755066 0.85 SMN1; SMN2 (0.51) ALDH1A1GAAHTTGPR55HPGD
SCHEMBL5756019 0.85 MAPT (0.53) ALDH1A1GAAHTTGPR55HPGD
SCHEMBL5759425 0.85 ALDH1A1 (0.51) ALDH1A1GAAHTTGPR55HPGD
SCHEMBL5759745 0.84 ALDH1A1 (0.50) ALDH1A1GAAHTTGPR55HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 ALDH1A1 311/4885GAA 134/4885HTT 3845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.